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Abstract
Background: Osteoporosis is a bone disease that can reduce both bone mass and bone strength. It can cause
serious fractures of bones, along with causing significant and even devastating physical, psychological and financial
consequences for patients and their family members. Many reports have revealed that the prevalence of decreased
bone density is higher in schizophrenic patients than in the non-psychological diseased population. The previous
report of our group revealed that chronic schizophrenia patients have poorer BUA levels since they were young as
compared to the general community population. Hyperprolactinemia and antipsychotics are reported to be among
the risk factors for osteoporosis in chronic schizophrenic patients.
Methods: 93 schizophrenic patients with severely poor adjusted BUA values and 93 age and gender matched
patients with normal adjusted BUA values from a previous survey study were selected. Data were collected via
questionnaires and via reviews of antipsychotic medications. Blood samples were drawn, and serum levels of
prolactin, estradiol, testosterone, magnesium, calcium, phosphate, osteocalcin, Cross-linked N-teleopeptide of type I
collagen (NTX), thyroid hormone and parathyroid hormone were checked. The association between BUA levels and
serum levels of the above items, along with the type of received antipsychotic medication, was evaluated.
Results: There was no significant association found between reduced BUA levels and serum prolactin, calcium,
phosphate, osteocalcin, NTX, thyroid stimulating hormone and parathyroid hormone levels. There was also no
association between BUA levels and types of currently received antipsychotics. There was no association between
BUA levels and menstruation condition in female patients. Hypermagnesemia had a borderline association with
classical and combined (classical and atypical) antipsychotic medications in male patients. Nevertheless,
hypermagnesemia is a significant protective factor of reduced BUA levels in female patients. Hyperprolactinemia
had a significant association with classical and combined antipsychotic medications in female patients.
Hyperprolactinemia, however, provides a protective effect on reduced BUA levels in male patients. There was no
significant association found between serum prolactin level and the type of antipsychotic medication received.
Conclusions: The results of this study are in contrast with literature that has reported an association between
bone mass and serum prolactin levels, serum magnesium levels and type of received antipsychotics. Further study
to investigate the pathophysiological process and the association between bone mass and serum prolactin level,
serum magnesium level and specific antipsychotics is necessary.
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Osteoporosis is a skeletal disorder that is characterized
by compromised bone strength. It is typically thought to
be age-related [1]. In an osteoporotic bone, bone
strength and bone stiffness are so severely deteriorated
that fractures can occur with minimal trauma. Either
the decrease of bone density, bone quality or both can
cause osteoporosis. The NIH Consensus Development
Conference defined osteoporosis as, “a disease character-
ized by low bone strength, leading to enhanced bone
fragility and a consequent increase in fracture risk” [2].
Fractures caused by osteoporosis can have significant
and even devastating physical, psychological and finan-
cial consequences on patients and their families [3,4].
Schizophrenia is a chronic, severe and disabling brain
disorder. It is a devastating disorder for most people
who are afflicted and is very costly for families and
society. Onset of symptoms typically occurs in young
adulthood [5], between the ages of 15 and 25. The pre-
valence in the United States is about 1% [6]. Schizophre-
nia occurs in all societies regardless of class, color,
religion and culture. There ar e ,h o w e v e r ,s o m ev a r i a -
tions in terms of incidence and outcomes for different
groups of people. The prevalence is around 0.5 to 1%
from country to country [5,7-16]. Schizophrenia patients
are significantly more likely to have one or more
chronic medical conditions. Hypothyroidism, chronic
obstructive pulmonary disease, diabetes, hepatitis C,
fluid/electrolyte disorders and nicotine abuse/depen-
dence have been reported to have higher incidence rates
in schizophrenia patients [17-20]. Osteoporosis is
another disease that has been reported to have higher
prevalence in schizophrenia patients than in the general
population [21].
Early onset of poor BUA levels in chronic schizophre-
nia patients without a further BUA level decrease during
the aging process was reported in an earlier survey con-
ducted by our group [22]. A decrease of BUA levels that
is found during menopausal transition in the female
general population is not found in female schizophrenic
patients. This study is designed to evaluate the associa-
tion between BUA levels and different types of received
antipsychotics (classical or atypical), serum prolactin,
calcium, phosphate, osteocalcin, Cross-linked N-teleo-
peptide of type I collagen (NTX), thyroid stimulating
hormone (TSH), parathyroid hormone level and men-
struation condition.
Methods
Study population
93 chronic schizophrenic patients with severely poor
adjusted BUA levels, as determined by heel QUS-II mea-
surement, from our previous bone mass survey study
[22] agreed to enter the study. Another group of 93 age
and gender matched patients with normal adjusted BUA
levels, as determined by heel QUS-II measurement, in
the same study were selected. Reduced bone mass is
defined as a T score equal or less than -2.5 computed
f r o mB U Ad a t ao fQ U SI I .T h e s e1 8 6c h r o n i cs c h i z o -
phrenic patients were all aged 20 years and older. They
were all inpatients of the Department of Psychiatry at
Yuli Veterans Hospital in Taiwan, ROC, from 2003 to
2004. As of 2007, all were still inpatients of the unit.
Psychiatrists at Yuli Veterans Hospital diagnosed all
patients according to DSM-IV criteria. Exclusion criteria
included any other medical diseases or use of medica-
tions known to develop osteoporosis or to affect bone
mass. Patients having received their current antipsycho-
tics less than one year or having received medication for
osteoporosis were excluded as well. The study was
approved by the medical ethics policy of the Institu-
tional Review Board Committee at Yuli Veterans Hospi-
tal (serial No. 94-09-04A). As per this policy, all subjects
were informed of the use of their medical information
and of the blood drawing, and gave their consent.
Laboratory tests, questionnaire and history review
All patients received a questionnaire regarding their gen-
eral data, major disease history, current medications and
previous medication history. Menstruation cycle condi-
tion was also included in the questionnaire for female
patients. Psychiatrists of Yuli Veterans Hospital reviewed
the medical history of these patients in regards to the
antipsychotic medications. Medical history in the inpati-
ent and outpatient departments of Yuli Veterans Hospital
were both included. These patients were classified into
classical, mixed group (neuroleptic medication combines
classical and atypical antipsychotics) and atypical group
according to the current antipsychotics they were receiv-
ing. Blood samples were drawn in the morning. Samples
were processed and analyzed as soon as possible in the
clinical laboratory of Yuli Veterans Hospital. The labora-
tory has passed ISO9001® and ISO15189® qualifications.
Serum prolactin and TSH levels were measured with che-
miluminescent immunoassay (Beckman Access®). Serum
calcium, magnesium and phosphate levels were measured
using Dade Behring RxL Max®. Other tests were per-
formed at Union Clinical Laboratory in Taiwan. Blood
samples were frozen at -78°C during preservation and
transportation. Serum Osteocalcin level was measured
using the electrochemiluminescence method of Roche
using Elecsys 2010®. Serum PTH, estradiol and testoster-
one levels were measured using the chemiluminescence
method of Bayer using ADVIA Centaur®. Serum NTX
was measured with the ELISA method of Osteomark®
using BIO-RAD CODA®.
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All subjects were classified into two groups according to
BUA levels: normal BUA levels or severely reduced
BUA levels. Four logistic regression models were used
step by step. Each model distinguished between genders.
The first logistic regression model analyzed the associa-
tion between BUA levels and serum levels of prolactin,
calcium, phosphate, osteocalcin, NTX, TSH and para-
thyroid hormone, along with types of currently received
antipsychotics by gender. The association between the
type of antipsychotic medication currently received and
serum levels of prolactin, calcium, phosphate, osteocal-
cin, NTX, TSH and parathyroid hormone were analyzed
by the second logistic regression model. Interactions of
serum prolactin levels and serum estradiol/testosterone
levels were also tested in this model. The association
between serum prolactin levels and serum levels of cal-
cium, phosphate, osteocalcin, NTX, TSH and parathyr-
oid hormone by gender was analyzed in the third
logistic regression model. The fourth regression model
analyzed the association between BUA levels and men-
struation, serum levels of prolactin, estradiol and testos-
terone. Interaction between menstruation and serum
prolactin was analyzed in this model as well. All statisti-
cal calculations were conducted using the Stata 10/SE
system for Mac.
Results
The demographic data is shown in Additional file 1.
There were 48 normal BUA level and 48 reduced BUA
level male patients. In addition, there were 45 normal
BUA level and 45 reduced BUA level female patients.
Similar mean age and an equal number of cases in both
normal BUA level and reduced BUA level of both gen-
ders confirmed the age and gender matched parity. The
mean BUA value of the male normal and reduced BUA
level groups was 91.21 (±1.56) and 49.25 (±0.92), respec-
tively. The mean BUA value of the female normal and
reduced BUA level groups was 98.53 (±2.5) and 51.27
(±0.82), respectively.
The results, shown in Additional file 1, reveal that the
male reduced BUA level patients had lower serum pro-
lactin (26.91 ± 3.29 ng/ml vs. 39.70 ± 4.69 ng/ml), tes-
tosterone (436.48 ± 29.56 ng/dl vs. 476.13 ± 27.54 ng/
dl), phosphate (3.30 ± 0.09 mg/dl vs. 3.44 ± 0.08 mg/dl),
magnesium (2.13 ± 0.03 mg/dl vs. 2.19 ± 0.03 mg/dl),
osteocalcin (16.26 ± 0.96 ng/ml vs. 17.00 ± 0.88 ng/ml),
parathyroid hormone (21.23 ± 1.77 pg/ml vs. 28.68 ±
2.23 pg/ml) and thyroid stimulating hormone (1.63 ±
0.13 mIU/ml vs. 1.75 ± 0.13 mIU/ml) levels. The male
patients with reduced BUA levels had higher serum
estradiol (18.35 ± 1.95 pg/ml vs. 16.62 ± 1.49 pg/ml),
calcium (8.82 ± 0.05 mg/dl vs. 8.78 ± 0.05 mg/dl) and
NTX (10.14 ± 1.00 nM BCE vs. 9.90 ± 0.46 nM BCE)
levels. The male patients with reduced BUA levels dis-
played more cases of having received atypical antipsy-
chotics than the normal BUA level patients (29 cases vs.
25 cases).
The female reduced BUA level patients had
lower serum estradiol (37.65 ± 7.88 pg/ml vs. 51.95 ±
8.94 pg/ml), testosterone (46.14 ± 2.41 ng/dl vs. 55.25 ±
3.62 ng/dl), calcium (8.73 ± 0.06 mg/dl vs. 8.78 ± 0.07
mg/dl), phosphate (3.71 ± 0.07 v mg/dl s. 3.85 ± 0.10
mg/dl), magnesium (2.10 ± 0.03 mg/dl vs. 2.20 ± 0.03
mg/dl), NTX (11.22 ± 0.71 nM BCE vs. 11.38 ± 0.59
nM BCE) and parathyroid hormone (16.09 ± 1.19 pg/ml
vs. 29.88 ± 1.96 pg/ml) levels. The female reduced BUA
level patients had higher serum prolactin (62.83 ± 8.62
ng/ml vs. 55.60 ± 8.01 ng/ml), osteocalcin (18.6 ± 1.52
ng/ml vs. 16.09 ± 1.19 ng/ml) and thyroid stimulating
hormone (1.96 ± 0.18 mIU/ml vs. 1.56 ± 0.14 mIU/ml)
levels. The female reduced BUA level patients and nor-
mal BUA level patients had the same pattern of antipsy-
chotic usage.
Additional file 2 shows the results of the logistic
regression model with BUA level as the dependent vari-
able. Independent variables include serum levels of pro-
lactin, estradiol, testosterone, calcium, phosphate,
magnesium, THS, parathyroid hormone, osteocalcin and
NTX, along with the current antipsychotic medication.
The only significant association found was between
BUA levels and serum prolactin levels in male patients.
Hyperprolactinemia is a protective factor (odds ratio =
0.30, 95% confidence interval: 0.11 ~ 0.81) of reduced
BUA levels. In female patients, the only significant asso-
ciation was between serum magnesium levels and BUA
levels. Hypermagnesemia was found to be a protective
factor of reduced BUA levels (odds ratio = 0.25, 95%
confidence interval: 0.09 ~ 0.66). Atypical antipsychotic
use results in an odds ratio larger than one in male
patients but smaller than one in female patients.
Additional file 3 shows the results of the logistic
regression model with antipsychotics as the dependent
variable and serum levels of prolactin, estradiol, testos-
terone, calcium, phosphate, magnesium, thyroid stimu-
lating hormone, parathyroid hormone, osteocalcin and
NTX as independent variables. Only the serum prolactin
level was found to be significantly associated with the
received antipsychotics in female patients, but it was not
found to be significant in male patients. The association
between antipsychotic medications and serum magne-
sium levels was found to be borderline significant in
male patients (p = 0.074), but was not significant in
female patients. There was no significant association
between the type of antipsychotic medication and serum
levels of estradiol, testosterone, calcium, phosphate,
TSH, parathyroid hormone, osteocalcin and NTX in
either gender. Interaction between serum prolactin
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tosterone in males) was tested in the same model and
was not found to be significant.
Additional file 4 reveals the results of the association
between serum prolactin levels and serum levels of
estradiol, testosterone, calcium, phosphate, magnesium,
TSH, parathyroid hormone, osteocalcin and NTX.
There was no male patient with a serum estradiol
level lower than the normal range in the sample; there-
fore, estradiol was dropped in all of the logistic regres-
sion models. There was only one male patient with
serum phosphate levels and serum NTX levels higher
than normal range in the study; therefore, serum levels
of phosphate and NTX were dropped in the logistic
regression model. There were only two male patients
with serum TSH levels higher than normal; therefore,
the serum TSH level was dropped in the logistic regres-
sion model. In female patients, there was only one case
with serum testosterone levels lower than the normal
range, so the serum testosterone level was dropped in
the logistic regression models.
Another logistic regression model was generated with
BUA level as the dependent variable. Age, serum mag-
nesium level, serum prolactin level and antipsychotic
medication were the independent variables. Menstrua-
tion status was also an independent variable in the
female group. The results are shown in Additional file 5.
The only significant factor found was high serum mag-
nesium level, which was found to be a protective factor
of reduced BUA level in female patients. In male
patients, the only significant factor found was high
serum prolactin level, which was also found to be a pro-
tective factor of reduced BUA levels. Interaction
between gender and serum prolactin level was insignifi-
cant, as was the interaction between gender and serum
magnesium level. There was also no significant interac-
tion between serum prolactin level and menstruation
status.
The results reveal that the serum magnesium level is
significantly associated with BUA level condition in
female patients and is insignificant in male patients.
Serum prolactin level is significantly associated with
BUA level condition only in male patients but is not sig-
nificant in female patients. The effect of serum magne-
s i u ml e v e la n ds e r u mp r o l a c t i nl e v e lo nB U Al e v e li s
not the same in different genders. There is a borderline
association between serum magnesium level and present
antipsychotic medication in male patients, and there is a
significant association between serum magnesium level
and BUA levels only in female patients. In contrast, the
serum prolactin level is significantly associated with the
current antipsychotic medication in female patients and
significantly associated with BUA level in male patients.
Discussion
In this study, hypermagnesemia displays a borderline
association with classical or mixed antipsychotics in male
patients. Hypermagnesemia, however, provides a signifi-
cant protective effect on BUA levels in female patients.
Constipation is a common medical problem in chronic
schizophrenia patients admitted in the chronic care unit
of Yuli Veterans Hospital. Therefore, many patients
receive magnesium oxide as a laxative. This may be the
cause of the high serum magnesium levels. Magnesium
has been reported to possibly inhibit calcification of
osteoids in in vitro experiments. Hypermagnesemia inhi-
bits mineralization of collagen in vivo and in vitro [23]
and was reported to cause abnormalities in metaphyses
in neonates [24]. According to these reports, elevated
serum magnesium levels should correlate with reduced
bone mass. Nevertheless, hypermagnesemia is a signifi-
cant protection factor on reduced BUA levels in this
study. This result is in contrast with previously reported
results. The mechanism of hypermagnesemia being a
protective factor of reduced BUA levels in female patients
should be investigated further. Possible confounders may
exist that were not considered in this study.
Hyperprolactinemia is significantly associated with
classic or mixed antipsychotics in female patients in this
study. Hyperprolactinemia provides a significant protec-
tive effect on reduced BUA levels in male patients. This,
however, is also in contrast with previous reports in
literature.
Many research projects have reported that hyperpro-
lactinemia correlates with poor bone mass in schizo-
phrenia patients. This is caused either by
hyperprolactinemia itself or by a process of resulting
hypogonadism. Hyperprolactinemia has been reported
with classic antipsychotic drugs [25]. Hyperprolactine-
mia caused by the administration of many kinds of neu-
roleptics was suspected to suppress gonadotropins and
gonadal hormones [26-28]. Chlorpromazine, the oldest
antipsychotic medication, has been reported to disturb
calcification of bones [29]. Higher doses of prolactin-
raising antipsychotic medications are associated with
higher serum prolactin levels. Higher doses of prolactin-
raising medications are associated with hyperprolactine-
mia and lower BMD [28]. Serum prolactin level is nega-
tively correlated with BMD value in the lumbar spine
and hip, but it is only significant over the hip area.
Neither testosterone nor estradiol was shown to influ-
ence the relationship between serum prolactin level and
BMD to a significant level in a 16-subject study [30].
Low BMD values and hypogonadism were reported in
young schizophrenic women with hyperprolactinemia
who were treated with prolactin-raising antipsychotics
[31].
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standard deviation lower in hyperprolactinemic women
[1]. Coss et al. reported that prolactin might have a
direct inhibitory effect on osteoblasts [32].
On the contrary, there are also many projects report-
ing different results. Halbreich et al. reported serum
prolactin levels do not correlate with BMD in women
but negatively correlate with BMD in men [26]. Becker
et al. performed a study involving 26 female, premeno-
pausal schizophrenic subjects. In their work, BMD
values were similar in the hyperprolactinemia and nor-
mal prolactin level subjects both at the lumbar and
femoral neck region. Nevertheless, the adjusted bone
speed of sound was significantly lower in the hyperpro-
lactinemia group at the radius and phalanx [33]. No sta-
tistical correlation between circulating prolactin and
bone speed of sound has also been reported [34,35].
Greenspan et al. reported that BMD correlated with the
duration of hyperprolactinemia but not with the degree
of hyperprolactinemia [36]. The Z-score of BMD value
is correlated with the duration of treatment in high pro-
lactin level patients but not in normal prolactin level
patients [37]. Elevated serum prolactin levels are not
associated with BMD in vertebral or hip regions in a
prospective study. Hyperprolactinemia, however, has a
direct impact on the rate of bone metabolism, both in
bone formation and in bone resorption [38]. Lean et al.
reported that there is no evidence that antipsychotic-
induced hyperprolactinemia is an independent risk fac-
tor for osteoporosis in schizophrenia patients [39].
Many research projects have reported that hyperpro-
lactinemia induced hypogonadism is correlated with
poor bone mass in schizophrenia patients. Hyperprolac-
tinemia and the subsequent hypogonadal state are a
couple of the reported causes of low bone mass in schi-
zophrenia patients [25,31,37,40-42]. Some projects, how-
ever, have reported that prolactin has a direct effect on
bone and is not related to hypogonadal state and ame-
norrhea [26,27,34,35,43]. There is no association
between hyperprolactinemia with serum estradiol levels
and serum testosterone levels in this study. There is also
no association between antipsychotic medication and
serum estradiol levels in female and serum testosterone
levels in male patients.
Atypical antipsychotics were reported to contribute to
less osteoporosis and have fewer hyperprolactinemia
side effects than classic neuroleptics [44]. Some atypical
antipsychotics, like Risperidone, however, have been
reported to be associated with hyperprolactinemia and
osteoporosis [33,45-47]. Hyperprolactinemia has not
been previously reported as being a protective factor of
reduced BUA levels in male patients, as it is in this
study. Further study is necessary to clarify the associa-
tion between exactly prescribed antipsychotics and bone
density and to find the pathophysiological process
between hyperprolactinemia and severe bone mass loss.
There is no significant association between the type of
prescribed antipsychotics and bone mass condition in
this study. The type of antipsychotic medication pre-
scribed is associated with hyperprolactinemia in female
patients. Nevertheless, hyperprolactinemia does not
associate with bone mass condition in females and is a
protective factor for reduced bone mass in male
patients. Hypermagnesemia is a protective factor for
reduced BUA level in female patients but is borderline
associated with antipsychotic medication in male
patients. The association between hypermagnesemia,
hyperprolactinemia, antipsychotic medication and
reduced BUA level is modified by gender. That may be
the reason there is no significant association between
the type of antipsychotic drugs and BUA level condition.
The pathophysiological processes of the effects of mag-
nesium and prolactin on bone need further study to
explore this issue.
Conclusions
In this study, hyperprolactinemia and hypermagnesemia
do not associate with types of antipsychotics. Hyperpro-
lactinemia was found to be a protective factor of
reduced BUA levels in male patients, and hypermagne-
semia was found to be a protective factor in female
patients. Bone metabolism markers do not correlate
with serum prolactin levels and type of antipsychotic.
There is no correlation between BUA level condition
and serum sex hormone levels. Interaction between
serum sex hormone levels and prolactin levels also does
not exist. There is no significant association between
serum calcium and phosphate levels and BUA levels in
schizophrenia patients. There is also no significant asso-
ciation between serum calcium, phosphate level and
type of antipsychotic medication.
Some of the results are not as the same as in previous
reports. Confounders, such as exact medication, not
included in this study may be the reason for the dissimi-
lar results. Modulating factors other than the reported
risk factors may also exist. Ethnic difference is another
possible reason for the different results.
U s eo fu l t r a s o n o g r a p h i ca ssessments instead of DXA
scans and the assessment of bone mass at only one loca-
tion are two of the limitations of this study. The role of
ultrasound in diagnosing osteoporosis and accessing risk
of fracture needs further study. Nevertheless, it is still a
portable and inexpensive method of bone mass screen-
ing [48]. Case control studies have their limitations in
studying pathophysiological processes. Dosage of anti-
psychotics, duration of treatment and physical activity
were not included, and these are other limitations. The
pathophysiological process is still important in
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matic fractures in chronic schizophrenic patients has
been reported to be about 25% [21]. Prospective com-
prehensive studies of bone dynamics in individuals with
first-episode schizophrenia, as well as in patients treated
with various medications, are needed in order to charac-
terize the problem(s) and to develop relevant treatment
and prevention strategies [49].
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